Medical Devices - Diabetes Management & Insulin Delivery Systems
Strategic Profile
Beta Bionics has established itself as a key leader in the durable insulin pump market, as evidenced by sales force productivity, pharmacy channel coverage, and gross margin profile. The company achieved 54% net sales growth in 2025 to $100.3M and more than doubled its installed user base, while guiding 2026 revenue to $130–$135M.
Cyborg Score Rationale
Strong revenue growth (54% YoY) and user adoption (129% increase in installed base) demonstrate traction in the growing insulin pump market. However, the company posted a $73.2M net loss in 2025, and Block & Leviton is investigating Beta Bionics for potential securities law violations, creating near-term uncertainty despite compelling commercial momentum.
Top Insights
Pharmacy Benefit Plan (PBP) channel sales surged 295% YoY in Q4 2025, demonstrating successful expansion of distribution channels beyond traditional DME with high-30s percentage of Q4 patient starts reimbursed through pharmacy.
Installed customer base reached 35,011 users in Q4 2025, up 129% YoY, indicating rapid market penetration and product acceptance.
Pipeline includes Patch Pump (tubing-free insulin pump) and Bihormonal iLet combining insulin and glucagon automation for advanced diabetes management.
Recent legal investigation (Feb 2026) has created volatility; stock fell 35% in January 2026 before recovering, suggesting market volatility and trust concerns among investors.
Named Competitors
t:slim X2 with Control-IQ — Insulin pump with automated glucose control system
Medtronic 780G — Hybrid closed-loop insulin pump system
Omnipod 5 — Tubeless automated insulin pump
Recent Developments
(February 2026) Reported Q4 2025 revenue of $32.1M (+57% YoY) and full-year 2025 revenue of $100.3M (+54%); guided 2026 revenue to $130–$135M
(January 2026) Analyst coverage initiated with mixed ratings; Lake Street raised price target to $40, while TD Cowen initiated Hold recommendation
(February 2026) Securities fraud investigation announced by Block & Leviton; stock experienced significant volatility with 35% decline in January
Open the full interactive Beta Bionics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.